0.31
0.31 (0%)
As of Apr 17, 2025
Enzo Biochem Inc [ENZ]
Source:
Company Overview
Enzo Biochem, Inc. has operated as a life sciences company for over 45 years. The primary business of Enzo today is conducted through its Life Sciences division (“Enzo Life Sciences”), which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.
| Country | United States |
| Headquarters | farmingdale, new york |
| Phone Number | 5167555500 |
| Industry | services |
| CEO | Kara Cannon |
| Website | www.enzo.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $7.3 |
| Operating Profit | $-1.6 |
| Net Income | $-1.5 |
| Net Cash | $-12.1 |
Profit Ratios
| Gross Margin | $3.8 |
| Operating Margin | -21.8 |
| Profit as % of Revenues | -246.6% |
| Profit as % of Assets | -2% |
| Profit as % of Stockholder Equity | -3.3% |
Management Effectiveness
| Return on Equity | -3.3% |
| Return on Assets | -2.3% |
| Turnover Ratio | 9.6% |
| EBITA | $-1.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $67.5 |
| Total Liabilities | $20.9 |
| Operating Cash Flow | $-11 |
| Investing Cash Flow | $4.5 |
| Financing Cash Flow | $-5.5 |
